Trials / Completed
CompletedNCT05112666
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United Kingdom Cohort (OSCAR-UK)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,601 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants). When clots occur, cancer patients carry a higher risk of recurring clots and more likely to bleed on blood thinning treatments. Therefore, it is critical to use blood thinners that optimize the safety and benefits. There are two main types of blood thinners that are recommended. The tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). Clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type. We aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK. |
| DRUG | other DOACs | Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK. |
| DRUG | LMWH | Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK. |
Timeline
- Start date
- 2021-12-02
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
- First posted
- 2021-11-09
- Last updated
- 2023-04-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05112666. Inclusion in this directory is not an endorsement.